Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508792 | 0.89 | CA12 (0.45) | HTTCA1CA12CA7CA14 | |
| SCHEMBL28869534 | 0.83 | CA1 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL21361488 | 0.81 | ALDH1A1 (0.49) | CA1CA2CA12CA7CA14 | |
| SCHEMBL8281581 | 0.81 | CA12 (0.48) | HTTCA12CA7CA14ALDH1A1 | |
| SCHEMBL5889230 | 0.80 | CA1 (0.47) | CA1CA2CA12CA7CA14 | |
| SCHEMBL15925135 | 0.77 | CA12 (0.41) | HTTCA12CA7CA14NPY5R | |
| SCHEMBL2029967 | 0.76 | PPARA (0.46) | CA1CA2CA12CA7CA14 | |
| SCHEMBL2361421 | 0.74 | GNAI3 (0.49) | CA1CA2CA12CA7CA14 | |
| SCHEMBL24667126 | 0.73 | HTT (0.45) | HTTALDH1A1POLB | |
| SCHEMBL20988344 | 0.73 | CNR2 (0.42) | HTTCA12CA7CA14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732896-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| US-7060817-B2 | Sulfonamide anions as catalysts for NCO oligomerization | BAYER MATERIALSCIENCE AG (DE) | 2006-06-13 | — | — | US | disclosed |
| US-20050033005-A1 | Sulfonamide anions as catalysts for NCO oligomerization | BAYER MATERIALSCIENCE AG (DE) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | HTT 1521/4885CA1 4774/4885CA2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.